Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European HTA Highlights: Discounts Soften NICE Approach But Germany’s IQWiG Shows Its Teeth

Executive Summary

It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.

You may also be interested in...



NICE’s Tecfidera Restrictions In MS Leave It Fighting For U.K. Market Share

Biogen Idec get nod after providing more data, but restrictions imposed mean Tecfidera is unlikely to leap ahead of a packed field.

Biogen’s Tecfidera Hit At NICE By Data Shortage, Functional Unblinding

NICE has demanded more data and analyses for Biogen Idec’s MS champion, Tecfidera, before it clears a drug expected to be a worthy opponent for Novartis’ Gilenya.

Projecting Market Access Success For Early-Stage Pharma Assets: Getting Past The Hurdles

All too often, pharmaceutical companies and investors put up hurdles, but they can and must identify indications and assets with high future market access potential in early stages by adjusting the early screening and evaluation process.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054370

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel